Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Farmers Insurance
Deloitte
Cipla
Express Scripts
Dow
McKesson
AstraZeneca
Cerilliant

Generated: May 21, 2018

DrugPatentWatch Database Preview

Olaparib - Generic Drug Details

or, see our see our flat-rate plans

« Back to Dashboard

What are the generic sources for olaparib and what is the scope of olaparib freedom to operate?

Olaparib
is the generic ingredient in one branded drug marketed by Astrazeneca Pharms and is included in two NDAs. There are eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Olaparib has two hundred and sixty-five patent family members in forty-eight countries.

There are two drug master file entries for olaparib. One supplier is listed for this compound.
Summary for olaparib
International Patents:265
US Patents:8
Tradenames:1
Applicants:1
NDAs:2
Drug Master File Entries: 2
Suppliers / Packagers: 1
Bulk Api Vendors: 96
Clinical Trials: 145
Patent Applications: 341
DailyMed Link:olaparib at DailyMed
Pharmacology for olaparib

US Patents and Regulatory Information for olaparib

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca Pharms LYNPARZA olaparib TABLET;ORAL 208558-002 Aug 17, 2017 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Astrazeneca Pharms LYNPARZA olaparib TABLET;ORAL 208558-002 Aug 17, 2017 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Astrazeneca Pharms LYNPARZA olaparib CAPSULE;ORAL 206162-001 Dec 19, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Astrazeneca Pharms LYNPARZA olaparib TABLET;ORAL 208558-001 Aug 17, 2017 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Non-Orange Book US Patents for olaparib

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,662,818 Phthalazinone derivatives ➤ Try a Free Trial
7,351,701 Therapeutic compounds ➤ Try a Free Trial
7,750,006 Phthalazinone derivatives ➤ Try a Free Trial
9,566,276 Phthalazinone derivatives ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Supplementary Protection Certificates for olaparib

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0150012 00136 Estonia ➤ Try a Free Trial PRODUCT NAME: OLAPARIIB;REG NO/DATE: EU/1/14/959 18.12.2014
00726 Netherlands ➤ Try a Free Trial PRODUCT NAME: OLAPARIB, EN ZOUTEN EN; REGISTRATION NO/DATE: EU/1/14/959/001 20141216
680 Luxembourg ➤ Try a Free Trial PRODUCT NAME: OLAPARIB AINSI QUE DES SELS ET DES SOLVATES DE CELUI-CI. FIRST REGISTRATION: 20141218
15/016 Ireland ➤ Try a Free Trial PRODUCT NAME: OLAPARIB, AND SALTS AND SOLVATES THEREOF; REGISTRATION NO/DATE: EU/1/14/959/001 20141216
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Moodys
Queensland Health
Mallinckrodt
Farmers Insurance
UBS
Cantor Fitzgerald
Deloitte
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.